thiotepa has been researched along with Neutropenia in 16 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the present study was to evaluate the safety and efficacy of oral fluconazole for empirical antifungal therapy in neutropenic patients with persistent fever." | 9.11 | Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation. ( Hardan, I; Maor, Y; Stemmer, SM, 2004) |
| "We evaluated the pharmacokinetics and pharmacodynamics of high-dose paclitaxel (HDP) monotherapy (825 mg/m2 continuous infusion over 24 h) with peripheral blood progenitor cell (PBPC) and G-CSF support in 17 women with metastatic breast cancer." | 9.09 | The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ( Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT, 2001) |
| "Thirty-eight women with responsive metastatic breast cancer received high-dose cyclophosphamide (3 to 6 g/m2 over 4 days), thiotepa (400 to 800 mg/m2), and novobiocin (0." | 9.08 | Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. ( Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995) |
| "The dose-limiting toxicities were interstitial pneumonitis and mucositis with moderately severe diarrhea (n = 3) and rash (n = 3)." | 6.69 | Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. ( Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M, 2000) |
| " The aim of the present study was to evaluate the safety and efficacy of oral fluconazole for empirical antifungal therapy in neutropenic patients with persistent fever." | 5.11 | Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation. ( Hardan, I; Maor, Y; Stemmer, SM, 2004) |
| "We evaluated the pharmacokinetics and pharmacodynamics of high-dose paclitaxel (HDP) monotherapy (825 mg/m2 continuous infusion over 24 h) with peripheral blood progenitor cell (PBPC) and G-CSF support in 17 women with metastatic breast cancer." | 5.09 | The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ( Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT, 2001) |
| "Thirty-eight women with responsive metastatic breast cancer received high-dose cyclophosphamide (3 to 6 g/m2 over 4 days), thiotepa (400 to 800 mg/m2), and novobiocin (0." | 5.08 | Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. ( Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995) |
| "The study was designed to determine the toxicity, feasibility, and effectiveness of high-dose cyclophosphamide (6 g/m2), thiotepa (500 mg/m2) and carboplatin (800 mg/m2 (CTCb) with hematopoietic rescue as consolidation after standard-dose adjuvant chemotherapy treatment of primary high-risk breast cancer." | 5.08 | Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer. ( Escudero, A; Fernández-Rañada, JM; López-Lorenzo, JL; López-Pascual, J; Pérez-Carrión, R; Tomás, JF, 1997) |
| " We conclude that, independent of effects on neutropenia, severe and cumulative platelet toxicity precludes further escalation of thiotepa dose despite the use of GM-CSF." | 5.07 | Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. ( Hudes, GR; LaCreta, FP; McAleer, C; Miller, LL; Nash, S; O'Dwyer, PJ; Ozols, RF; Schilder, R, 1992) |
| "The dose-limiting toxicities were interstitial pneumonitis and mucositis with moderately severe diarrhea (n = 3) and rash (n = 3)." | 2.69 | Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. ( Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M, 2000) |
| "Chromosomal aberrations were quantitated using traditional Giemsa stain." | 1.33 | The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration. ( Balis, F; Bates, S; Cole, D; Egorin, MJ; Flynn, BM; Fojo, T; Knutsen, T; Langham, G; Rao, VK; Ried, T; Steinberg, SM; Wangsa, D, 2005) |
| "As compared with metastatic breast cancer (MBC), high risk breast cancer showed a 2." | 1.31 | Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. ( Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (56.25) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreri, AJ | 1 |
| Cwynarski, K | 1 |
| Pulczynski, E | 1 |
| Ponzoni, M | 1 |
| Deckert, M | 1 |
| Politi, LS | 1 |
| Torri, V | 1 |
| Fox, CP | 1 |
| Rosée, PL | 1 |
| Schorb, E | 1 |
| Ambrosetti, A | 1 |
| Roth, A | 1 |
| Hemmaway, C | 1 |
| Ferrari, A | 1 |
| Linton, KM | 1 |
| Rudà, R | 1 |
| Binder, M | 1 |
| Pukrop, T | 1 |
| Balzarotti, M | 1 |
| Fabbri, A | 1 |
| Johnson, P | 1 |
| Gørløv, JS | 1 |
| Hess, G | 1 |
| Panse, J | 1 |
| Pisani, F | 1 |
| Tucci, A | 1 |
| Stilgenbauer, S | 1 |
| Hertenstein, B | 1 |
| Keller, U | 1 |
| Krause, SW | 1 |
| Levis, A | 1 |
| Schmoll, HJ | 1 |
| Cavalli, F | 1 |
| Finke, J | 1 |
| Reni, M | 1 |
| Zucca, E | 1 |
| Illerhaus, G | 1 |
| Stemmer, SM | 1 |
| Maor, Y | 1 |
| Hardan, I | 1 |
| Rao, VK | 1 |
| Knutsen, T | 1 |
| Ried, T | 1 |
| Wangsa, D | 1 |
| Flynn, BM | 1 |
| Langham, G | 1 |
| Egorin, MJ | 2 |
| Cole, D | 1 |
| Balis, F | 1 |
| Steinberg, SM | 1 |
| Bates, S | 1 |
| Fojo, T | 1 |
| Ridola, V | 1 |
| Grill, J | 1 |
| Doz, F | 1 |
| Gentet, JC | 1 |
| Frappaz, D | 1 |
| Raquin, MA | 1 |
| Habrand, JL | 1 |
| Sainte-Rose, C | 1 |
| Valteau-Couanet, D | 1 |
| Kalifa, C | 1 |
| Chang, Q | 1 |
| Hanks, S | 1 |
| Akard, L | 1 |
| Thompson, J | 1 |
| Harvey, K | 1 |
| English, D | 1 |
| Jansen, J | 1 |
| Kennedy, MJ | 1 |
| Armstrong, DK | 1 |
| Huelskamp, AM | 1 |
| Ohly, K | 1 |
| Clarke, BV | 1 |
| Colvin, OM | 1 |
| Grochow, LB | 1 |
| Chen, TL | 1 |
| Davidson, NE | 1 |
| Spitzer, G | 1 |
| Dunphy, FR | 1 |
| Petruska, PJ | 1 |
| Velasquez, WS | 1 |
| Adkins, DR | 1 |
| Williams, SF | 1 |
| Lee, WJ | 1 |
| Bender, JG | 1 |
| Zimmerman, T | 1 |
| Swinney, P | 1 |
| Blake, M | 1 |
| Carreon, J | 1 |
| Schilling, M | 1 |
| Smith, S | 1 |
| Williams, DE | 1 |
| Oldham, F | 1 |
| Van Epps, D | 1 |
| Tomás, JF | 1 |
| Pérez-Carrión, R | 1 |
| Escudero, A | 1 |
| López-Lorenzo, JL | 1 |
| López-Pascual, J | 1 |
| Fernández-Rañada, JM | 1 |
| Stahel, RA | 1 |
| Jost, LM | 1 |
| Honegger, H | 1 |
| Betts, E | 1 |
| Goebel, ME | 1 |
| Nagler, A | 1 |
| Hornedo, J | 1 |
| Sola, C | 1 |
| Solano, C | 1 |
| Lluch, A | 1 |
| Benavides, M | 1 |
| López López, J | 1 |
| García Conde, J | 1 |
| Cortés-Funes, H | 1 |
| Vahdat, LT | 2 |
| Papadopoulos, K | 1 |
| Balmaceda, C | 1 |
| McGovern, T | 1 |
| Dunleavy, J | 1 |
| Kaufman, E | 2 |
| Fung, B | 1 |
| Garrett, T | 1 |
| Savage, D | 1 |
| Tiersten, A | 1 |
| Ayello, J | 1 |
| Bagiella, E | 1 |
| Heitjan, D | 1 |
| Antman, K | 1 |
| Hesdorffer, C | 1 |
| Prince, HM | 1 |
| Rischin, D | 1 |
| Toner, GC | 1 |
| Seymour, JF | 1 |
| Blakey, D | 1 |
| Gates, P | 1 |
| Eerhard, S | 1 |
| Chapple, P | 1 |
| Quinn, M | 1 |
| Brettell, M | 1 |
| Juneja, S | 1 |
| Wolf, M | 1 |
| Januszewicz, EH | 1 |
| Richardson, G | 1 |
| Scarlett, J | 1 |
| Briggs, P | 1 |
| Papadopoulos, KP | 1 |
| Huang, M | 1 |
| Troxel, AB | 1 |
| Balmaceda, CM | 1 |
| Hesdorffer, CS | 1 |
| Morabito, F | 1 |
| Irrera, G | 1 |
| Oliva, E | 1 |
| Console, G | 1 |
| Martino, M | 1 |
| Pucci, G | 1 |
| Messina, G | 1 |
| Barbaro, P | 1 |
| Palazzo, S | 1 |
| Iacopino, P | 1 |
| O'Dwyer, PJ | 1 |
| LaCreta, FP | 1 |
| Schilder, R | 1 |
| Nash, S | 1 |
| McAleer, C | 1 |
| Miller, LL | 1 |
| Hudes, GR | 1 |
| Ozols, RF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Tra[NCT01011920] | Phase 2 | 126 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 trials available for thiotepa and Neutropenia
| Article | Year |
|---|---|
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Topics: Acute Kidney Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System | 2016 |
Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemo | 2004 |
Maturation of mobilized peripheral blood progenitor cells: preclinical and phase I clinical studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Differentiation; | 1995 |
Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.
Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos | 1995 |
Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin | 1996 |
Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, | 1997 |
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1997 |
[Multicentric prospective, randomized study of the role of filgrastim (G-CSF) after transplant of hematopoietic progenitor cells mobilized with G-CSF in patients with cancer of the breast].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modal | 1997 |
Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami | 1998 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; | 2000 |
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2001 |
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
Topics: Aged; Drug Administration Schedule; Drug Evaluation; Female; Granulocyte-Macrophage Colony-Stimulati | 1992 |
4 other studies available for thiotepa and Neutropenia
| Article | Year |
|---|---|
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
Topics: Animals; Area Under Curve; Azure Stains; Bone Marrow Cells; Chromosome Aberrations; Chromosome Paint | 2005 |
High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Busulfan; Cerebellar Neoplasms; Child | 2007 |
Tandem transplants in solid tumors: marrow versus peripheral stem cell transplant: peripheral blood cells as now practiced are not the whole answer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Transplantation; Breas | 1993 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplast | 2001 |